IsoTis Receives FDA Clearance for Accell Family o...( IRVINE California August 20 /- Is...)

IRVINE, California, August 20 /PRNewswire-FirstCall/ -- IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that it received a letter dated August 15, 2007 from the US Food and Drug Administration ("FDA"), clearing the Accell Family of Products for marketing in the US as Class II medical devices.

The Accell Family of Products includes Accell 100, Accell Connexus and Accell Total Bone Matrix, as well as a new Accell product that is not currently marketed. The products are indicated for use as bone graft extenders in the spine, extremities and pelvis, or as bone void fillers in extremities and pelvis.

Pieter Wolters, President and CEO of IsoTis said, "We are very pleased with the final outcome of our discussions with the FDA. With the clearance of the Accell Family of Products we can now focus on advancing the clinical benefits of Accell for both patients and surgeons. The expected merger with Integra LifeSciences will further enhance our ability to successfully market these products going forward. "

About IsoTis

IsoTis is an orthobiologics company that develops, manufactures and markets proprietary products for the treatment of musculoskeletal diseases and disorders. IsoTis' current orthobiologics products are bone graft substitutes that promote the regeneration of bone and are used to repair natural, trauma-related and surgically-created defects common in orthopedic procedures, including spinal fusions. IsoTis' current commercial business is highlighted by its Accell line of products, which the company believes represents the next generation in bone graft substitution.

On August 7, 2007 Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") and
'/>"/>

SOURCE IsoTis Inc Copyright©2007 PR Newswire.

0 GOOD